dipyridamole: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
dipyridamole: clinical details
Prescribing considerations
- Confirm the formulation and licensed indication because the selected oral suspension is licensed only as an adjunct to anticoagulation for prosthetic heart valves.
- Use caution in severe coronary artery disease, unstable angina, recent myocardial infarction, left ventricular outflow obstruction, haemodynamic instability, coagulation disorders and myasthenia gravis.
- Inform surgical and cardiac-stress-testing teams about oral dipyridamole; additional intravenous dipyridamole requires specialist coordination.
- Consider formulation excipients in patients with relevant allergies or hereditary fructose intolerance.
Contraindications and cautions
- Hypersensitivity to dipyridamole or any component of the selected product.
- The selected prolonged-release capsule containing sucrose should not be used in specified rare hereditary disorders of fructose or glucose handling.
- The oral suspension contains maltitol and should not be used in hereditary fructose intolerance.
Monitoring
- Assess clinically for bleeding, bruising and perioperative haemorrhage.
- Review new or worsening angina, tachycardia, hypotension, dizziness or syncope.
- Review treatment if myasthenia gravis symptoms change.
- During breastfeeding, monitor the infant for gastrointestinal effects, irritability, rash, bruising or bleeding.
Clinical pharmacology
Dipyridamole inhibits cellular adenosine uptake and phosphodiesterase activity, increasing platelet cyclic nucleotide signalling and reducing aggregation. It also promotes prostacyclin activity and causes vasodilation. It is highly protein-bound, undergoes hepatic glucuronidation and is eliminated mainly through bile and faeces.
Formulation and product differences
- Modified- or prolonged-release capsules contain coated pellets and must be swallowed whole; product-specific food and alcohol instructions differ.
- The oral suspension must be shaken thoroughly and taken before meals. It contains maltitol, propylene glycol, a small amount of ethanol and parahydroxybenzoates.
- Selected capsules cover stroke or TIA prevention and prosthetic-valve use, whereas the selected suspension is licensed only for prosthetic-valve-associated thromboembolism prevention alongside anticoagulation.
dipyridamole preparations and strengths
Modified-release capsule
Route: Oral
Strengths: 200 mg
Oral suspension
Route: Oral
Strengths: 50 mg/5 mL
dipyridamole interactions
Check prescribed, over-the-counter and complementary products with a pharmacist or prescriber.
Anticoagulants and other antiplatelets
Effects on clotting may be additive, increasing bleeding risk.
Aspirin or ibuprofen used for pain
These can increase bleeding risk and should not be added unless a clinician confirms they are appropriate. Prescribed antiplatelet aspirin is a separate context.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.